MORF vs. PTGX, AKRO, XNCR, DAWN, DVAX, KNSA, TARO, RCUS, KURA, and ANIP
Should you be buying Morphic stock or one of its competitors? The main competitors of Morphic include Protagonist Therapeutics (PTGX), Akero Therapeutics (AKRO), Xencor (XNCR), Day One Biopharmaceuticals (DAWN), Dynavax Technologies (DVAX), Kiniksa Pharmaceuticals (KNSA), Taro Pharmaceutical Industries (TARO), Arcus Biosciences (RCUS), Kura Oncology (KURA), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical preparations" industry.
Morphic (NASDAQ:MORF) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership.
94.3% of Morphic shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 28.1% of Morphic shares are owned by insiders. Comparatively, 5.0% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Protagonist Therapeutics has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Protagonist Therapeutics had 14 more articles in the media than Morphic. MarketBeat recorded 16 mentions for Protagonist Therapeutics and 2 mentions for Morphic. Protagonist Therapeutics' average media sentiment score of 0.90 beat Morphic's score of 0.82 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Morphic has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.
Morphic presently has a consensus price target of $51.50, indicating a potential upside of 79.94%. Protagonist Therapeutics has a consensus price target of $38.00, indicating a potential upside of 34.61%. Given Morphic's higher probable upside, equities research analysts clearly believe Morphic is more favorable than Protagonist Therapeutics.
Protagonist Therapeutics received 183 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 59.73% of users gave Protagonist Therapeutics an outperform vote while only 59.54% of users gave Morphic an outperform vote.
Protagonist Therapeutics' return on equity of 43.42% beat Morphic's return on equity.
Summary
Protagonist Therapeutics beats Morphic on 13 of the 16 factors compared between the two stocks.
Get Morphic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MORF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MORF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
